Actionable Pharmacogenomic Biomarkers in Breast Cancer Therapy: From Drug Response to Clinical Implementation
Breast cancer therapy increasingly depends on biomarkers that identify drug sensitivity, acquired resistance, or treatment-related toxicity. Pharmacogenomic information becomes clinically relevant when a molecular result changes drug selection, dose, treatment sequence, or monitoring; consequently, germline and som...